Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

The U.S.'s drug regulator has approved Roche's Susvimo drug for the treatment of diabetic macular edema, the leading cause of diabetes-related blindness, the pharmaceutical company said.

The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...